Runx2 Suppression by miR-342 and miR-363 Inhibits Multiple Myeloma Progression
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
In multiple myeloma, abnormal plasma cells accumulate and proliferate in the bone marrow. Recently, we observed that Runx2, a bone-specific transcription factor, is highly expressed in multiple myeloma cells and is a major driver of multiple myeloma progression in bone. The primary goal of the present study was to identify Runx2-targeting miRNAs that can reduce tumor growth. Expression analysis of a panel of miRNAs in multiple myeloma patient specimens, compared with healthy control specimens, revealed that metastatic multiple myeloma cells express low levels of miR-342 and miR-363 but high levels of Runx2. Reconstituting multiple myeloma cells (CAG) with miR-342 and miR-363 reduced the abundance of Runx2 and the expression of metastasis-promoting Runx2 target genes RANKL and DKK1, and suppressed Runx2 downstream signaling pathways Akt/β-catenin/survivin, which are required for multiple myeloma tumor progression. Intravenous injection of multiple myeloma cells (5TGM1), stably overexpressing miR-342 and miR-363 alone or together, into syngeneic C57Bl/KaLwRij mice resulted in a significant suppression of 5TGM1 cell growth, decreased osteoclasts and increased osteoblasts, and increased antitumor immunity in the bone marrow, compared with mice injected with 5TGM1 cells expressing a miR-Scramble control. In summary, these results demonstrate that enhanced expression of miR-342 and miR-363 in multiple myeloma cells inhibits Runx2 expression and multiple myeloma growth, decreases osteolysis, and enhances antitumor immunity. Thus, restoring the function of Runx2-targeting by miR-342 and miR-363 in multiple myeloma cells may afford a therapeutic benefit by preventing multiple myeloma progression. Implications: miR-342 and miR-363–mediated downregulation of Runx2 expression in multiple myeloma cells prevents multiple myeloma progression. Mol Cancer Res; 16(7); 1138–48. ©2018 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
How many drug targets are there?
Overington, J. P., Al-Lazikani, B., & Hopkins, A. L. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2199 · Cited by 3,505 · cited 1×
“Unfortunately, transcription factors are often considered to be non-druggable, as targeting these intracellular proteins lacking enzymatic activity remains challenging (11, 12).”
BackgroundHopkins, A. L., & Groom, C. R. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd892 · Cited by 3,305 · cited 1×
“Unfortunately, transcription factors are often considered to be non-druggable, as targeting these intracellular proteins lacking enzymatic activity remains challenging (11, 12).”
BackgroundRegulatory T cells in cancer immunotherapy
Tanaka, A., & Sakaguchi, S. (2017) · Cell Research · doi:10.1038/cr.2016.151 · Cited by 1,860 · cited 1×
“Moreover, increases in the numbers of immunosuppressive Tregs andBregs and a decrease in the number of pDCs in the tumor microenvironment predicts worse survival for patientswith various types of cancer (42, 43).”
BackgroundRescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-dependent
Kamphorst, A. O., Wieland, A., Nasti, T., Yang, S., Zhang, R., Barber, D. L., Konieczny, B. T., Daugherty, C. Z., Koenig, L., Yu, K., et al. (2017) · Science · doi:10.1126/science.aaf0683 · Cited by 1,015 · cited 1×
“Previous studies have demonstrated that blockade of programmed cell death-1 (PD-1) and T-cell immunoglobulin domain and mucin domain-containing molecule-3 (Tim-3) signaling in CD8þ T cells enhances the cytotoxic response of CD8þ T cells by production of effector cytokines such as IFN-g and TNF-a (34, 35).”
BackgroundPathogenesis of myeloma bone disease
Roodman, G. D. (2009) · Leukemia · doi:10.1038/leu.2008.336 · Cited by 398
Tumor-Induced Osteoclast miRNA Changes as Regulators and Biomarkers of Osteolytic Bone Metastasis
Ell, B., Mercatali, L., Ibrahim, T., Campbell, N., Schwarzenbach, H., Pantel, K., Amadori, D., & Kang, Y. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.09.008 · Cited by 266 · cited 1×
“Recent studies have demonstrated that miRNA-mediated targeting of osteoclasts can be used to treat osteolytic bone disease (18).”
Background
Cited by
Guo, B., Xiao, C., Liu, Y., Zhang, N., Bai, H., Yang, T., Xiang, Y., Nan, Y., Li, Q., Zhang, W., et al. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s270636 · Cited by 21
Non-Coding RNAs in Multiple Myeloma Bone Disease Pathophysiology
Raimondi, L., De Luca, A., Giavaresi, G., Raimondo, S., Gallo, A., Taiana, E., Alessandro, R., Rossi, M., Neri, A., Viglietto, G., et al. (2020) · Non-Coding RNA · doi:10.3390/ncrna6030037 · Cited by 16
Chen, H., Zhao, Y., Zhang, J., Xie, Y., & Jin, M. (2021) · Cytokine · doi:10.1016/j.cyto.2021.155495 · Cited by 11
(2021) · PubMed Central · Cited by 11
Metadata
- Authors
- Gowda, P. S., Wildman, B. J., Trotter, T. N., Xu, X., Hao, X., Hassan, M. Q., & Yang, Y.
- Venue
- Molecular Cancer Research
- Published
- 2018-07-01
- Volume
- 16
- Issue
- 7
- Pages
- 1138-1148
- ISSN
- 1541-7786 (ISSN-L)
- 1557-3125
- OpenAlex
- W2795018339
- Cited by
- 52
- References
- 6
- FWCI
- 3.04
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Runx2 Suppression by miR-342 and miR-363 Inhibits Multiple Myeloma Progression. https://app.cochat.ai/papers/10.1158/1541-7786.mcr-17-0606
- The paper
- Gowda, P. S., Wildman, B. J., Trotter, T. N., Xu, X., Hao, X., Hassan, M. Q., & Yang, Y. (2018). Runx2 Suppression by miR-342 and miR-363 Inhibits Multiple Myeloma Progression. Molecular Cancer Research. https://doi.org/10.1158/1541-7786.mcr-17-0606
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.